Skip to main content
TipRanks
Go Ultimate75% OFF

SciBase Holding AB (5J30) AI Stock Analysis

0 Followers
DE:5J30

SciBase Holding AB

(Frankfurt:5J30)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Revenue GrowthSustained multi-year revenue expansion indicates growing adoption of SciBase’s dermatology technology and improving commercial reach. Continued top-line growth can support operating leverage over time, provided the company converts its expanding revenue base into improved profitability.
Negative Factors
Deepening LossesLosses have widened materially despite strong revenue growth, showing that the current operating cost base is absorbing the benefits of expansion. Persistent negative margins weaken financial resilience and make future funding, scale efficiencies, and disciplined cost control increasingly important.

SciBase Holding AB (5J30) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%40%DE:5J30-78.52%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.56M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.7
Beta (1Y)
14.31
Revenue Growth
59.03%
EPS Growth
46.21%
Country
Germany
Employees
46
Sector
General
Sector Strength
55
Industry
Medical - Devices

SciBase Holding AB Business Overview & Revenue Model

Company Description

SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key...

SciBase Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:5J30 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:SECT.BSE:SECT.B74OutperformSEK 63.88B100.1230.26%0.70%13.94%5.70%
SE:PAXSE:PAX57NeutralSEK 1.54B-302.47-1.22%―34.05%-144.96%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:SEZISE:SEZI55NeutralSEK 532.17M-5.46-35.44%―18.56%28.11%
SE:ACARIXSE:ACARIX45NeutralSEK 213.86M-5.42-96.06%―40.61%32.63%
SE:SPECSE:SPEC40UnderperformSEK 20.68M-0.12-57.15%――78.15%

* General Sector Average

Performance Comparison

-75%-50%-25%0%25%DE:5J30SE:PAXSE:SEZISE:SPECSE:SECT.BSE:ACARIXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:5J30 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:5J30SciBase Holding AB0.72-2.63-78.52%
SE:PAXPaxman AB66.004.006.45%
SE:SEZISenzime AB3.38-1.63-32.44%
SE:SPECSpectraCure AB0.01-0.12-89.55%
SE:SECT.BSectra AB Class B327.4046.6416.61%
SE:ACARIXAcarix AB0.17-0.10-36.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.